Drug Trial Radar · NCT07015268
A Clinical Study of KLH-2109 in Patients With Endometriosis
Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
288
Planned (sponsor's estimate)
Start
Jun 9, 2025
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To verify the non-inferiority of KLH-2109 to leuprorelin acetate in a double-blind manner in terms of efficacy in endometriosis patients with pelvic pain.
Conditions
- Endometriosis
Interventions
KLH-2109Drug
\- KLH-2109 tablet: Oral administration \- Leuprorelin acetate placebo: Subcutaneous administration
Leuprorelin acetateDrug
\- KLH-2109 placebo tablet: Oral administration \- Leuprorelin acetate: Subcutaneous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the maximum NRS score for pelvic pain during 28 days prior to 12 weeks of the investigational product treatmentTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Multiple Locations, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.